Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
Our Research today shows that the stock is due for a 99% increase in it’s stock valuation within a 6 to 12 month duration.  Yahoo Finance Analyst Report indicates a 160% increase. Our STA Research rating indicates the stock as Strong Buy.
https://www.stocktargetadvisor.com/stock/USA/NSD/SVRA
